Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586724 | 1.00 | TLR2 (0.55) | TLR2PTPN1KMT2AACEMDM2 | |
| SCHEMBL16726198 | 0.95 | TLR2 (0.52) | TLR2PTPN1KMT2AACEMDM2 | |
| SCHEMBL31212512 | 0.95 | TLR2 (0.59) | TLR2PTPN1KMT2AACEMDM2 | |
| SCHEMBL30099539 | 0.95 | PTPN1 (0.57) | TLR2PTPN1KMT2AACE | |
| SCHEMBL12658035 | 0.92 | PTPN1 (0.58) | TLR2PTPN1KMT2AMDM2MDM4 | |
| SCHEMBL29602166 | 0.91 | TLR2 (0.58) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL29352159 | 0.91 | TLR2 (0.58) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL29514436 | 0.91 | TLR2 (0.58) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL3624369 | 0.91 | TLR2 (0.58) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL29466503 | 0.91 | TLR2 (0.58) | TLR2KMT2AMDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279272-A1 | RESIDUALIZING LINKERS AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279272-A1 | RESIDUALIZING LINKERS AND USES THEREOF | CD44, CD47, MTCL3 | TLR2 2129/4885PTPN1 1980/4885KMT2A 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.